A physical performance measure for individuals with mucopolysaccharidosis type I

被引:18
|
作者
Haley, Stephen M.
Pinkham, Maria A. Fragala
Dumas, Helene M.
Ni, Pengsheng
Skrinar, Alison M.
Cox, Gerald F.
机构
[1] Boston Univ, Hlth & Disabil Res Inst, Boston, MA 02215 USA
[2] Genzyme Corp, Clin Res, Cambridge, MA USA
来源
关键词
D O I
10.1017/S0012162206001216
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The purpose of this article is threefold: (1) to describe the development, reliability, and validity of a revised physical performance measure for individuals with mucopolysaccharidosis type I (MPS 1); (2) to standardize the test on a normal sample; and (3) to compare results from a selected sample of individuals with MPS I with age-based centiles. The MPS Physical Performance Measure (MPS-PPM) is composed of eight timed functional tasks (FT-8) and two endurance tasks with a modified Energy Expenditure Index for comfortable walking (CW) and fast walking (FW) speeds. Age norms were derived from a convenience sample of 150 typically developing children and adolescents (75 males, 75 females; mean age 11y 2mo, [SD 4y 5mo]; range 5-22y). Using a Rasch model for speed tests and confirmatory factor analysis, we established the unidimensionality of the FT-S. Interrater reliability of the FT-8 (intraclass correlation [ICC]=0.98) and test-retest reliability of the FT-8 (ICC=0.96), CW (ICC=0.91), and FW (ICC=0.83) were good. Results of the age-based profiles in 10 individuals with MPS I (five males, five females; mean age 14y 2mo [SD 7y 6mo]; range 6-29y) indicate that the amount of time needed to perform functional tasks is severely affected by the disease, and most individuals were at or below the fifth centile for their age. The patterns of limitations in endurance were more varied. These results suggest the utility of using this revised MPS-PPM to identify the extent of limitation in age-expected physical performance. Implications for using the MPS-PPM for monitoring physical performance changes during clinical interventions are discussed.
引用
收藏
页码:576 / 581
页数:6
相关论文
共 50 条
  • [41] Open issues in Mucopolysaccharidosis type I-Hurler
    Rossella Parini
    Federica Deodato
    Maja Di Rocco
    Edoardo Lanino
    Franco Locatelli
    Chiara Messina
    Attilio Rovelli
    Maurizio Scarpa
    Orphanet Journal of Rare Diseases, 12
  • [42] Molecular Analysis of Vietnamese Patients with Mucopolysaccharidosis Type I
    Can, Ngoc Thi Bich
    Tran, Dien Minh
    Bui, Thao Phuong
    Nguyen, Khanh Ngoc
    Nguyen, Hoang Huy
    Nguyen, Tung Van
    Hwu, Wuh-Liang
    Tomatsu, Shunji
    Vu, Dung Chi
    LIFE-BASEL, 2021, 11 (11):
  • [43] Mucopolysaccharidosis Type I and Bilateral Optic Disc Edema
    Gratton, Sean M.
    Neerukonda, Thanuja
    NEURO-OPHTHALMOLOGY, 2019, 43 (06) : 394 - 396
  • [44] Effect of discontinuing of laronidase in a patient with mucopolysaccharidosis type I
    Anbu, AT
    Mercer, J
    Wraith, JE
    JOURNAL OF INHERITED METABOLIC DISEASE, 2006, 29 (01) : 230 - 231
  • [45] New recommendations for the care of patients with mucopolysaccharidosis type I
    Bay, Luisa
    Amartino, Hernan
    Antacle, Alejandra
    Arberas, Claudia
    Berretta, Adriana
    Botto, Hugo
    Cazalas, Mariana
    Copiz, Adriana
    De Cunto, Carmen
    Drelichman, Guillermo
    Espada, Graciela
    Eiroa, Hernan
    Fainboim, Alejandro
    Fano, Virginia
    Guelber, Norberto
    Maffey, Alberto
    Parisi, Claudio
    Pereyra, Marcela
    Remondino, Rodrigo
    Schenone, Andrea
    Specola, Norma
    Staciuk, Raquel
    Zuccaro, Graciela
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2021, 119 (02): : E121 - E128
  • [46] Losartan improves cardiovascular disease in mucopolysaccharidosis type I
    Gonzalez, Esteban A.
    Poletto, Edina
    Tavares, Angela M. V.
    Giugliani, Roberto
    Matte, Ursula
    Baldo, Guilherme
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S57 - S57
  • [47] Phenotype prediction for mucopolysaccharidosis type I by in silico analysis
    Li Ou
    Michael J. Przybilla
    Chester B. Whitley
    Orphanet Journal of Rare Diseases, 12
  • [48] Source document verification in the Mucopolysaccharidosis Type I Registry
    Verhulst, Karien
    Artiles-Carloni, Laura
    Beck, Michael
    Clarke, Joe T. R.
    Correa Neto, Jordao
    Cox, Gerald F.
    Fernhoff, Paul M.
    Guffon, Nathalie
    Kong, Yuan
    Martins, Ana Maria
    Tylki-Szymanska, Anna
    Whitley, Chester B.
    Wijburg, Frits A.
    Wraith, Edward J.
    Koepper, Catherine M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 (07) : 749 - 752
  • [49] Impaired Medullary Hematopoiesis in Murine Mucopolysaccharidosis Type I
    Viana, Gustavo
    Paredes-Gamero, Edgar Julian
    Martins, Ana Maria
    D'Almeida, Vania
    MOLECULAR GENETICS AND METABOLISM, 2012, 105 (02) : S63 - S63
  • [50] Corneal Cloudiness: A Presenting Feature of Mucopolysaccharidosis Type I
    Surbhi Khurana
    Parul Chawla Gupta
    Ranjan Kumar Behera
    Himanshi Singh
    Jagat Ram
    Indian Journal of Pediatrics, 2022, 89 : 291 - 291